Macrophage Activation Syndrome in the Setting of Rheumatic Diseases

W Winn Chatham1

  • 1Department of Internal Medicine, University of Nevada, Las Vegas, Las Vegas, NV, USA. w.chatham@unlv.edu.

Insights

Macrophage activation syndrome (MAS) in rheumatic diseases can stem from severe flares or infections. Identifying infectious triggers is crucial for managing MAS, alongside treatments like corticosteroids and biologics targeting IL-1/IL-6.

Area of Science:

  • Rheumatology
  • Immunology
  • Infectious Diseases

Background:

  • Macrophage activation syndrome (MAS) is a severe complication in rheumatic disorders.
  • MAS can arise from severe disease flares (e.g., adult-onset Still's disease, SLE) or infectious triggers.
  • Identifying infectious triggers is critical for effective MAS management in rheumatic patients.

Purpose of the Study:

  • To emphasize the importance of investigating infectious triggers in rheumatic disease patients presenting with MAS.
  • To outline current therapeutic strategies for MAS.

Main Methods:

  • Review of clinical presentations and etiologies of MAS in rheumatic diseases.
  • Analysis of management approaches for MAS, including immunosuppressive and targeted biologic therapies.

Main Results:

  • MAS in some rheumatic diseases (e.g., SLE, Still's disease) is linked to disease flares.
  • In other rheumatic conditions, MAS is frequently associated with viral or infectious agents.
  • Effective management involves treating infections and using combined therapies.

Conclusions:

  • Prompt identification of infectious triggers is essential for rheumatic disease patients with MAS.
  • Treatment strategies combine addressing the underlying infection with immunosuppression (corticosteroids, calcineurin inhibitors) and cytokine blockade (anti-IL-1, anti-IL-6).
  • Targeting the cytokine storm is key to managing MAS and its associated rheumatic complications.